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Clinical studies on nasal topical medications require the 
standardization of “nasosinusal normality” in order to establish 
control groups through a specific evaluation of the upper 
airways. Aim: to standardize the evaluation of candidates for 
control groups in clinical studies on nasal topical medications. 
Material and Methods: healthy male volunteers of 18 to 50 
years of age, asymptomatic from the nasosinusal standpoint 
were subjected to a sequential and excluding assessment 
made up of clinical evaluation, immediate hypersensitivity 
skin test, saccharin test, flexible nasofibroscopy and nasal 
cytology. Study design: Cross-sectional contemporary cohort. 
Results: Of the 33 people originally enrolled, 14 (42.4%) 
were excluded for clinical reasons. Of the 19 remaining, 
2 (10.5%) had atopy diagnosed in the skin test and were 
excluded. 17 were tested with saccharin and presented 
normal mucociliary clearance. Evaluation by nasal endoscopy 
showed abnormality in 2 cases (11.8%) and these were 
excluded. The remaining 15 were submitted to nasal cytology, 
which proved normal, representing 45.5% of those initially 
included. Conclusion: The proposed protocol for sequential 
and excluding evaluation was effective in defining candidates 
for the establishment of control groups in clinical studies on 
nasal topical medications.
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INTRODUCTION
Nasosinusal physiology is important for promoting 
quality of life and preventing respiratory disease, especially 
in large cities, where there are many aggressors to the 
respiratory mucosa, such as low atmospheric humidity, a 
high concentration of pollutants, and indiscriminate use of 
air conditioning systems.1 Diseases such as rhinitis, sinusi-
tis, and airway viral infections reach high prevalence and 
morbidity rates among these populations, leading to other 
even more severe conditions, such as asthma, bronchitis, 
pneumonias, and emphysema.2 Topical nasal medication 
aims to clean and hydrate the mucosa (saline solutions,3,4 
nasal gel,5-7 and ringer lactate solution8) and to administer 
corticosteroids topically.6 It is also possible to use this route 
for systemic drugs, given its extensive capillary network.9 
Controlled clinical studies are thus needed to demonstrate 
the efficacy and safety of drugs given by this route.
Characterizing “normal” or healthy subjects naso-
sinusally is important in studies of topical nasal drugs, 
both for PHASE 1 trials, which classically include healthy 
subjects, and in PHASE 2, 3 and 4 trials, in which it is ne-
cessary to confirm the nosological entity being studied and 
control groups.10 In defining a control group, it is necessary 
to make sure that subjects have no systemic diseases that 
might affect their general health; such diseases included 
arterial hypertension, diabetes mellitus, and chronic renal 
failure. Additionally, factors that may interfere pharma-
cologically with the drugs being studied - such as use of 
other medications - should be excluded.
The gender and age of subjects should also be 
considered, since female hormones, for instance, may 
affect the nasal mucosa, altering nasosinusal physiology,11 
and elderly populations may present typical changes of 
ageing in the nasal musoca.9 For this reason, most of the 
clinical trials for evaluating topical drugs chooses adult 
males as their study populations, except when the study 
drug is specifically indicated for the female, pediatric or 
elderly populations. Environmental conditions may also 
affect such choices;1,9,12 geographically distant populations 
may be exposed to very different conditions of air humi-
dity, temperature, presence of pollutants, and irritative 
or allergenic agents, which compounds the difficulties of 
standardizing control groups and characterizing a healthy 
nasal mucosa.1,9,12
Anatomical features of the nose, such as septal 
deviation, turbinate hypertrophy, or polyps, and a history 
of surgery or recent airway infections, may also interfere 
with nasosinusal physiology. Other factors should also be 
taken into account, such as smoking, medication or use 
of illegal drugs by a nasal route.
We conducted a survey of nasosinusal conditions 
of a population declared as healthy and asymptomatic, 
recruited at a research center in the city of Campinas, Sao 
Paulo state, to define a test protocol aiming at standardi-
zing and demonstrating a status of nasosinusal health and 
“normalcy”, and to define selection and exclusion criteria 
for research subjects in clinical trials using topical nasal 
medication. We wrote a protocol that comprises a careful 
clinical evaluation, a sequential and excluding immediate 
hypersensitivity skin test, the saccharine test, flexible na-
sofibroscopy, and a nasal cytogram.
METHOD
This study was undertaken at the Scentryphar Pes-
quisa Clínica Ltda research center located in the city of 
Campinas, Sao Paulo state, with funding from Libbs Phar-
maceutical Ltd, and conforming to Brazilian and internatio-
nal guidelines for good clinical practices, established by the 
International Harmonization Conference (GCP - ICH), and 
also in conformity with the Helsinki Declaration principles 
defined by the World Medical Association (WMA). The 
Institutional Review Board of the Medical Science Scho-
ol, Campinas University - UNICAMP approved this study 
(number 1.046/2007). A free informed consent form was 
made in line with institutional requirements and applied 
to subjects that volunteered for this study.
Self-declared healthy, disease-free and nasosinusally 
asymptomatic male adults aged from 18 to 50 years were 
invited to participate in this study. A 5-step sequential 
evaluation was done, as follows:
Step 1: Clinical assessment (CA).
The following inclusion and exclusion criteria were 
defined in this step: inclusion criteria - healthy, male sub-
jects aged from 18 to 50 years, with no medical history of 
rhinitis, sinusitis, asthma or chronic bronchitis, able to sign 
the free informed consent form; exclusion criteria - having 
participated in any other clinical trial within the past one 
year, a medical history of upper airway viral infection 
or sinusitis within the last three weeks, having used any 
topical nasal medication within the last four week, having 
taken systemic corticosteroids, antihistaminic drugs or de-
congestion drugs within the last four weeks, a history of 
nasal or sinus surgery within the last five years, smoking or 
a history of smoking within the last five years, daily alcohol 
consumption and/or having used illicit drugs within the last 
two years. A general physical examination was also done in 
this phase, including body temperature, pulse and arterial 
pressure measurements, and anterior rhinoscopy. Cases 
not encompassed by the inclusion/exclusion criteria, or 
with findings in the physical examination, were excluded.
Step 2: Immediate hypersensitivity skin test (HT)
Subjects selected in step 1 (CA) underwent step 2 
(HT). Those positive for histamine (positive control) and 
negative for a 0.9% saline solution (negative control), 
standard acarid antigens (D. pteronyssinus, D. farinae, B 
tropicalis), fungi (A. alternata, C. herbarum, A. fumigatus), 
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cockroaches (B. germanica, P. americana), animals (Cannis 
familiaris, Fellis domesticus) and pollen (P. pratense, L. 
perenne, D. glomerata, F. pratensis) were considered fit 
for the next step. Other findings were taken as indicating 
abnormalities, and such subjects were excluded.
Step 3: Saccharine test (ST).
Subjects selected in step 2 (HT) underwent the ST 
in a controlled environment to evaluate mucociliary cle-
arance. Perceiving a sweet taste within 45 minutes was 
considered a normal result. Longer periods were consi-
dered as altered mucociliary clearance, and such subjects 
were excluded.
Step 4: Flexible nasofibroscopy (NF).
Subjects selected in step 3 (ST) underwent NF for 
an endoscopic anatomical and functional evaluation of 
the nasal cavities. The nasosinusal status was considered 
as normal when the following were absent: increased 
nasal discharge, altered aspect of the lower nasal turbi-
nate, the nasal mucosa or the middle meatus, obstructive 
septal deviation, and nasal polyps. Other findings were 
Frame 1. Technical guidelines for standardizing the procedures.
PROCEDURE Technique
Immediate Hypersensitivity Skin Test (HT)
1) Antisepsis with 70% alcohol-imbibed cotton of skin on the anterior portion of the 
subject’s forearm, allowing it to dry.
2) Drip 01 (one) drop of each reagent at least 2 cm from each other over the intact skin 
on the anterior portion of the forearm. Do not carry out the test less than 3 cm from the 
antecubital fossa and the subject’s wrist.
3) Puncture with the disposable puncture needle (acrylic polymer) pressing firmly at a 
45-90º angle, without rotating, for a second, over the drop placed on the subjects skin 
(use a puncture needle for each antigen).
4) Wait 20 minutes and then dry the drop with cotton or absorbing paper before rea-
ding:
4.1. Edema and erythema area measured in millimeters and compared with positive 
and negative controls. The final measurement, in millimeters, is the sum of the longitu-
dinal measure and the vertical measure divided by two.
4.2. Check the positivity of the "positive control" (histamine), which should be ≥ 3 mm. 
If negative, consider the test void and redo on another day.
4.3. Check the "negative control " (0.9% saline).
4.4. Check the result for all antigens. Positivity is a papule larger than 3 mm compared 
to the negative control. 
Saccharine Test (ST) 1) A respiratory irritating agent and dust-free room at 22º C (±2º C).
2) Deposit saccharine crystals in nostrils on the medial face of the lower turbinate, 1 
cm from the anterior margin of its head. Start counting the time.
3) The subject should remain seated, with the head horizontal, swallowing each 60 
seconds, breathing naturally through the nose and avoiding blowing the nose snee-
zing or coughing. Ask the subject to warn immediately if a sweet taste is perceived. If 
paroxystic sneezing and/or coughing occurs, repeat the test within two days.
Flexible Nasofibroscopy (NF)
1) Use a flexible nasofibroscope and topical anesthesia of the nasal cavity with 2% 
neotutocaine without vasoconstritor
2) Classify the following: lower turbinate (normal, hyperemic, pale or cyanotic); nasal 
discharge (normal, increased hyaline, increased mucoid or increased purulent); ante-
rior septal mucosa (normal, hyperemic or not intact - exulcerated/ulcerated); middle 
meatus (normal, edematous or polypoid degeneration); nasal polyp (absent or pre-
sent); septal deviation (absent/non-obstructive or obstructive - grade III areas 1,2,4)
Nasal Cytogram (NC)
1) Sample nasal cytogram by inserting the brush into the space between the nasal 
septum and the middle third of the superior portion of the lower turbinate, applying 5 
complete rotation movements in each nasal fossa (bilateral collection with the same 
brush).
2) Store the sample in a specific medium. 
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considered as indicating abnormalities, and such subjects 
were excluded.
Step 5: Nasal cytogram (NC).
Subjects selected in step 4 (NF) underwent NC to 
evaluate the cells in a nasal smear. Full and percentage 
counts were made of epithelial cells (columnar, flat and 
goblet) and leukocytes (polymorphonuclear, lymphocytes 
and eosinophils). Analysis of the nasal cytogram was con-
ducted at a reference laboratory (Fleury S.A).
Frame 1 shows the technical guidelines for carrying 
out the HT, the ST, NF, and NC.
RESULTS
There were 33 subjects included initially. Their 
mean age was 33.2 years. The CA revealed factors that 
could affect nasosinusal physiology in 14 of these sub-
jects (42.4%), which were excluded (Tables 1 and 6). Of 
the remaining 19 subjects (57.6% of the initial number) 
admitted to step 2 (HT), two cases had immediate hyper-
sensitivity to acarids (10.5%) and were excluded. No other 
hypersensitivity to antigens was seen in the remaining 
patients (Table 2).
ST and NF were done in 17 subjects. The mean 
absolute time in the ST was 2 minutes and 54 seconds, 
ranging from 1 min and 8 sec to 5 min and 23 sec (Table 
3). Obstructive septal deviation was found in 11.8% of 
subjects, which were excluded from the study (Table 4). 
Thus, 15 subjects underwent CN, which revealed predo-
minantly epithelial cells and rare leukocytes (Table 5).
Therefore, 15 subjects (45.5%) of the 33 subjects 
originally included were classified as candidates for control 
groups in studies of topical nasal drugs. Table 6 shows the 
excluding causes in various phases of the study.
DISCUSSION
The tests and exams applied in this study to stan-
dardize the selection and exclusion criteria of research 
subjects for control groups in clinical trials of topical nasal 
drugs are well-known diagnostic procedures in the scien-
tific literature, and have been used for safely assessing the 
nasal anatomy and physiology of subjects.3,12-19 Carrying 
out CA as the first selection step aimed at promptly evalu-
ating the general health status and factors that might affect 
nasosinusal physiology.
HT was chosen as the second step due to the pos-
Table 1. Results of the Clinical Assessment (CA).
 N Mean Standard deviation Median Minimum - Maximum
Age (years) 33 33.2 6.8 34 22.0 - 47.0
Body temperature (ºC) 33 36.0 0.4 36.1 35.1 - 36.8
Pulse (bpm) 33 64.7 6.9 66 50 - 80
Weight (Kg) 33 73.3 11.1 69.3 59.5 - 97.6
Systolic pressure (mmHg) 33 125.9 10.4 126.0 103.0 - 140
Dyastolic pressure (mmHg) 33 74.6 9.0 74.0 56.0 - 900
Height (m) 33 1.71 0.07 1.70 1.60 - 1.90
Race
Black: 8 (24,2%) Caucasian: 25 (75,8%)
Table 2. Results of the Immediate Hypersensitivity Skin Test (HT).
 N positive negative
Positive control 19 19 0
Negative control 19 0 19
D. pteronyssinus/D. farinae (ácaro 1) 19 2* 17
B. tropicalis (acarid 2) 19 1* 18
A. alternata, C. herbarum, A. fumigatus 19 0 19
B. germânica, P. americana 19 0 19
Canis familiaris 19 0 19
Fellis domesticus 19 0 19
P. pratense, L. perenne, D. glomerata, F. pratensis 19 0 19
* positive for acarids (n=2): one patient was positive for 2 antigens; another to only one
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sibility that atopy might affect the compliance to topical 
nasal therapy, as well as more serious nasal irritation. 
HT was applied to check for allergen hypersensitivity; 
the allergens were chosen based on the literature.12 Our 
results showed that even without specific complaints or a 
personal history of allergy, 10.5% of our study population 
were positive for one or more of the antigens we tested, 
which justified this test.
ST has been described in the literature as a repre-
sentative functional test of nasal mucociliary clearance; 
it correlates very well with radioisotope testing.13,14,20 Ra-
dioisotope testing is the gold standard, but is restricted to 
small groups because of exposure to ionizing radiation and 
cost.13,14,20 Thus, ST is a faster, practical and more economi-
cal option for evaluating nasal mucociliary clearance.13,14,20
Literature data on ST define a normal result when 
Table 3. Results of the Saccharine Test (ST).
N=17 Minutes / Seconds
Mean 2 / 54
Standard deviation 1 / 34
Median 2 / 32
Minimum - Maximum 1 / 08 - 5 / 23
Table 4. Results of Nasofibroscopy (NF).
 N Absent Present
Septal deviation 17 15 2
Nasal polyps 17 17 0
Nasal discharge 17 17 0
Altered lower turbinate 17 17 0
Altered mucosa of the 
anterior nasal septum
17 17 0
Altered middle meatus 17 17 0




Columnar 88.9% (± 12.7)













Table 6. Causes of exclusion by protocol phases.
initial n excluded causes of exclusion
CLINICAL ASSESSMENT (CA) 33 14 * (42,4%)
turbinate hypertrophy (n=5), history of smoking within last 5 years (n=2), 
upper airway viral infection or sinusitis within last 3 weeks (n=2), septal 
deviation (n=1), use of topical nasal medication, corticosteroids or antihis-
tamines within last 4 weeks (n=1), history of wheezing in childhood (n=1), 
daily consumption of alcohol (n=1), not meeting all inclusion criteria 
(n=1).
SKIN TEST (HT) 19 2 (10,5%) Positive for acarids (n=2)
SACCHARINE TEST (ST) 17 0 Not excluded.
FLEXIBLE NASOFIBROSCOPY (NF) 17 2 (11,7%) Obstructive septal deviation (n=2)
NASAL  CYTOGRAM (NC) 15 0 Not excluded
subjects report a sweet taste up to 30 minutes after the 
stimulus. This test is often used for screening purposes 
to find patients requiring more detailed assessments of 
mucociliary clearance.13 We found no case in which this 
parameter was altered; the mean result was below 3 
minutes. Subjects undergoing this test had already been 
selected in previous steps (CA and HT) to investigate 
nasosinusal symptoms.
NF is routinely done in otorhinolaryngology; it is 
very sensitive and specific for evaluating the anatomy 
and function of the nose.15,21 Topical anesthesia is needed 
for NF, which could have affected mucociliary beats and 
taste, which explained the sequence of procedures in this 
test (NF was done after ST). Our results revealed that in 
an asymptomatic population, about 11% of subjects had 
anatomical features that could have altered the applica-
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tion and dispersion of topical nasal drugs; underlying the 
importance of this test.
NC identifies the cell types in the respiratory muco-
sa, and is used in various clinical trials.16-18 The results 
revealed that our sample was within normal limits, accor-
ding to the literature;22,23 columnar cells predominated, 
there were few leukocytes and rare eosinophils. This 
results reflected the effectiveness of previous steps (CA, 
HT, ST and NF) for selecting “normal” subjects, since the 
prevalence of allergic rhinitis (10-30%) and acute rhino-
sinusitis (viral and bacterial) is high in the general popu-
lation.3,19 We would thus expect more inflammatory and/
or allergic manifestations. NC was chosen for this step in 
characterizing a control group because of its importance 
to investigate possible local effects of study drugs. NC was 
the final procedure in our selection sequence, because 
bleeding might occur when collecting the sample, which 
would interfere with NF and ST.
Notwithstanding the sensitivity and specificity of 
these procedures, CA should be considered as a funda-
mental assessment tool, as it detected factors affecting 
nasosinusal physiology in over 40% of the asymptomatic 
study sample. Furthermore, the selection sequence above 
was practical and rapidly done; all procedures were car-
ried out in a single visit, which avoids subjects having to 
return unnecessarily.
CONCLUSION
The examination protocol consisting of carrying out 
a careful clinical history, an immediate hypersensitivity 
skin test, the saccharine test, flexible nasofibroscopy, and 
a nasal cytogram, in sequence and excluding subjects at 
each step if indicated was effective and safe for selecting 
nasosinusally healthy subjects. Our results suggest that this 
protocol may be applied for standardizing the inclusion 
and exclusion criteria of research subjects for control 
groups in clinical trials on topical nasal medication, and 
to define the status of baseline physiological parameters in 
studies assessing the response of the nasosinusal mucosa 
to repeated and prolonged stimuli.
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